MELANOMASEQ : 1015862

Please provide most recent Pathology report.

MDFCPNGSMEL3 or 1015862

MELANOMASEQ panel components: BRAF, NRAS, KIT.
    
If you have any further questions, additional needs, or would like to speak with med fusion’s scientific staff, pathologists, or client services, please contact us at 972-966-7050/844-966-7050.

Tissue, Core Needle Biopsy (4-6 aspirates, 18 gauge needle preferred), Fine Needle Aspirate (FNA), or Malignant fluid in formalin fixed paraffin embedded block (FFPE). Tissue slides may be submitted.

Paraffin embedded Tissue: submit in sterile biohazard plastic bag. Slides: Unstained, positively charged, unbaked 5 micron sections; submit 10 FFPE in slide holder. Specimen to be tested must contain a minimum of 20 percent tumor.

Paraffin embedded Tissue: Ambient or on ice pack in summer; Slides: Ambient.

Paraffin embedded tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Decalcified tissue specimen.

Tuesday

8-10 days

Laboratory test results should always be considered in the context of clinical observations. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.

An interpretive report will be provided.

Disease-specific solid tumor panel intended to aid the oncologist in prioritizing standard of care therapy and clinical trial choices for patients with advanced stage melanoma.